Nanobiotix shares rocket up on a marginal success for soft tissue sarcoma; AstraZeneca wins pioneering PD-L1 OK in India
→ Shares of Nanobiotix (Euronext: NANO) soared after the biotech reported positive though marginal results for its Phase II/III study of NBTXR3 in soft tissue sarcoma. But the key outcome was not great. Nanobiotix reported that “twice as many patients (16.1% vs 7.9%) achieved a pathological Complete Response (pCR) with NBTXR3 compared to the control arm (p = 0.0448).” That’s barely a passing grade, but investors seemed to like it. The p-value on the secondary was an equally unimpressive 0.042. Its shares rocketed up 50% on the news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.